Facebook
Twitter
LinkedIn
Forward61st Kappa Psi Grand Council Convention Cleveland, OH
Pharmacists are medication experts. The CDC Opioid Guideline is a medication guideline. Within interprofessional teams, pharmacists are looked upon as the medication expert, thus needing a working knowledge of the medication guideline. Presenter: Mark Garofoli
It is important to recognize that beta-lactam allergy labels are common in the general population, however, the vast majority are not truly allergic. Efforts to de-label can be multidisciplinary and should be initiated by all clinicians, not limited to those from Allergy and Immunology. Pharmacists can play a direct role in obtaining patient drug allergy histories and recommending an approach to de-labeling. Presenter: Deanna McDaniel
This will help pharmacists in supporting prescribers’ understanding appropriate prescribing and coverage for anti-obesity medications. Presenter: Allison Fay
This activity will provide pharmacists a knowledge base to assist medical and behavioral health practitioners with determining if a specific LAI is appropriate for a patient seeking LAI treatment. These medications often require trials or lead-in dosing of equivalent oral medications and patient monitoring after injection that may need to be performed by clinic and not pharmacy staff. Presenter: Athena Borhauer
Target Audience
Pharmacist
Learning Objectives
Presenter: Mark Garofoli
1.Identify the specific recommendations within the 2022 CDC Opioid Guideline Update.
2.Recall the pain management best practices utilized prior to initiating opioid medications, and for chronic utilization.
3.Recall the morphine milligram equivalent (MME) factors of common prescription opioid medications.
Presenter: Deanna McDaniel
1.Review key updates on beta-lactam antibiotic drug allergies from the 2022 Drug Allergy Practice Parameter Update and how to incorporate these into practice.
2.Discuss the cross-reactivity of cephalosporins in penicillin allergic patients.
3.Review the appropriate management of beta-lactam antibiotic allergies and understand best practices for de-labeling penicillin allergies.
4.Take away practical applications to optimizing treatment in patients with beta-lactam drug allergies.
Presenter: Allison Fay
1.Review guideline recommendations for the management of obesity.
2.Compare current pharmacological interventions for obesity management in adult and pediatric patients.
3.Interpret insurance coverage, costs, and access for anti-obesity medications.
Presenter: Athena Borhauer
1.Describe the signs, symptoms, and diagnostic criteria of schizophrenia spectrum, alcohol use disorder, and opioid use disorder.
2.Discuss the benefit of using long-acting injectable medications over other medications forms for the above disease states.
3.Outline the mechanism of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic (if applicable) properties, adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for LAIs used for the above disease states.
4.Select an evidence-based drug therapy regimen (dose, drug, schedule, and duration of therapy) for a patient wanting to switch to an LAI medication to treat their specific disease state.
5.Review how to perform Z-track injection techniques.
6.Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
7.Identify essential information to discuss during patient education about LAI therapy.
Pharmacists are medication experts. The CDC Opioid Guideline is a medication guideline. Within interprofessional teams, pharmacists are looked upon as the medication expert, thus needing a working knowledge of the medication guideline. Presenter: Mark Garofoli
It is important to recognize that beta-lactam allergy labels are common in the general population, however, the vast majority are not truly allergic. Efforts to de-label can be multidisciplinary and should be initiated by all clinicians, not limited to those from Allergy and Immunology. Pharmacists can play a direct role in obtaining patient drug allergy histories and recommending an approach to de-labeling. Presenter: Deanna McDaniel
This will help pharmacists in supporting prescribers’ understanding appropriate prescribing and coverage for anti-obesity medications. Presenter: Allison Fay
This activity will provide pharmacists a knowledge base to assist medical and behavioral health practitioners with determining if a specific LAI is appropriate for a patient seeking LAI treatment. These medications often require trials or lead-in dosing of equivalent oral medications and patient monitoring after injection that may need to be performed by clinic and not pharmacy staff. Presenter: Athena Borhauer
Athena Borhauer, PharmD
Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS
Deanna McDaniel, PharmD, BCPS, BCACP
Allison Fay, PharmD, BCACP, BC-ADM, CPP
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (CPE)
This knowledge-based activity provides up to 4.0 contact hours of continuing pharmacy education credit.
Other Healthcare Professionals: Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 4.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.
- 4.00 Attendance